Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
Top Page
Vivos Therapeutics
(NASDAQ:VVOS)
47Neutral
Vivos Therapeutics (VVOS) vs. S&P 500 (SPY)
Market Cap
$18.32M
Dividend YieldN/A
Average Volume (3M)136.29K
Price to Earnings (P/E)―
Beta (1Y)1.99
Revenue Growth0.54%
EPS Growth66.35%
CountryUS
Employees114
SectorHealthcare
Sector Strength72
IndustryMedical - Devices
Share Statistics
EPS (TTM)-4.95
Shares Outstanding5,889,520
10 Day Avg. Volume59,121
30 Day Avg. Volume136,295
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.19
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.30Price Target Upside102.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Vivos Therapeutics Business Overview & Revenue Model
Company DescriptionVivos Therapeutics (VVOS) is a medical technology company that focuses on the development and commercialization of innovative treatments for patients with sleep-disordered breathing, including mild to moderate obstructive sleep apnea. The company's primary product is the Vivos System, a non-invasive, oral appliance therapy designed to remodel and enhance the upper airway, providing a therapeutic alternative to traditional CPAP machines. Vivos operates within the healthcare sector, specifically targeting dental and sleep medicine professionals to deliver its solutions.
How the Company Makes MoneyVivos Therapeutics generates revenue through the sale and distribution of the Vivos System, which is marketed to dental practices, sleep clinics, and healthcare providers. The company employs a business-to-business model, selling directly to practitioners who then provide the treatment to patients. Additionally, Vivos offers training and support services to practitioners for the implementation and use of their system. Revenue is also derived from licensing fees, subscription services for ongoing support, and partnerships or collaborations with dental practices and healthcare companies. The company's earnings are influenced by the adoption rate of its technologies among healthcare providers, as well as the overall awareness and demand for treatment of sleep-disordered breathing.
Vivos Therapeutics Financial Statement Overview
Summary
Vivos Therapeutics faces significant financial challenges, with persistent losses and a reliance on external financing. Despite a positive gross profit margin, the company struggles to convert revenue into profit. The balance sheet indicates manageable leverage but low equity, while cash flow issues highlight the need for strategic improvements.Income Statement
Vivos Therapeutics has shown a slight improvement in revenue with a growth rate of 5.65% in the TTM period compared to the previous year. However, the company continues to face significant challenges in profitability, with negative net and EBIT margins at -86.15% and -84.73% respectively. Gross profit margin remains relatively high at 59.74%, indicating some operational efficiency. The consistent negative net income is a concern, suggesting ongoing financial difficulties.42
Neutral
Balance Sheet
The company's balance sheet reflects a mixed picture. The debt-to-equity ratio is relatively low at 0.21, indicating manageable leverage. However, the return on equity (ROE) remains negative at -163.98%, highlighting inefficiencies in generating profits from shareholders' equity. The equity ratio is moderate at 49.95%, suggesting a balanced approach between equity and liabilities but also underscoring a weak equity base.35
Negative
Cash Flow
Vivos Therapeutics has struggled with negative free cash flow, despite a slight improvement in free cash flow growth of 0.67%. The operating cash flow to net income ratio is slightly positive at 0.99, indicating that operational cash generation is close to net income levels, albeit both are negative. The company relies heavily on financing activities to support its cash flows, which could pose risks in the long term.38
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 14.58M | 13.80M | 16.02M | 16.89M | 13.07M | 11.39M | Gross Profit |
| 8.71M | 8.27M | 10.02M | 12.60M | 10.41M | 8.66M | EBIT |
| -12.36M | -17.30M | -25.03M | -19.47M | -8.71M | -10.58M | EBITDA |
| -12.04M | -16.68M | -24.36M | -19.54M | -11.24M | -9.87M | Net Income Common Stockholders |
| -12.57M | -13.58M | -22.66M | -20.29M | -8.82M | -10.89M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 469.35K | 1.64M | 3.52M | 24.03M | 18.21M | 469.35K | Total Assets |
| 7.55M | 10.73M | 13.72M | 33.69M | 25.33M | 7.55M | Total Debt |
| 3.71M | 2.00M | 2.41M | 1.63M | 1.29M | 3.71M | Net Debt |
| 3.24M | 352.00K | -1.11M | -22.40M | -16.92M | 3.24M | Total Liabilities |
| 10.49M | 10.32M | 8.92M | 8.15M | 8.41M | 10.49M | Stockholders Equity |
| -2.94M | 411.00K | 4.80M | 25.54M | 16.92M | -2.94M |
| Cash Flow | Free Cash Flow | ||||
| -12.66M | -12.75M | -20.51M | -18.13M | -5.80M | -5.52M | Operating Cash Flow |
| -12.50M | -11.95M | -19.59M | -15.73M | -5.68M | -5.34M | Investing Cash Flow |
| -568.00K | -853.00K | -924.00K | -2.61M | -120.25K | 86.22K | Financing Cash Flow |
| 18.39M | 10.92M | 0.00 | 24.17M | 23.54M | 4.47M |
Vivos Therapeutics Technical Analysis
Negative
3.11
Price Trends
3.82
Negative
3.87
Negative
3.22
Negative
Market Momentum
-0.11
Positive
39.49
Neutral
19.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VVOS, the sentiment is Negative. The current price of 3.11 is below the 20-day moving average (MA) of 3.41, below the 50-day MA of 3.82, and below the 200-day MA of 3.22, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 39.49 is Neutral, neither overbought nor oversold. The STOCH value of 19.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VVOS.
Vivos Therapeutics Risk Analysis
Vivos Therapeutics disclosed 85 risk factors in its most recent earnings report. Vivos Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vivos Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $22.35B | 25.33 | 7.24% | 0.85% | 3.84% | -9.29% | |
72 Outperform | $353.73M | 7.50 | 27.04% | ― | -17.44% | 73.71% | |
60 Neutral | $3.30B | ― | -75.27% | ― | 20.13% | 10.05% | |
51 Neutral | $626.70M | ― | -22.87% | ― | 7.08% | 20.45% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
47 Neutral | $18.32M | ― | -325.98% | ― | 0.54% | 66.35% | |
43 Neutral | $2.07B | ― | -46.67% | ― | 18.82% | 19.76% |
* Healthcare Sector Average
Performance Comparison
VVOS
Vivos Therapeutics
3.11
-0.26
-7.72%
OFIX
Orthofix
16.06
2.00
14.22%
ZBH
Zimmer Biomet Holdings
113.18
-15.43
-12.00%
SMLR
Semler Scientific
36.20
7.25
25.04%
NVCR
NovoCure
18.86
3.37
21.76%
IRTC
Irhythm Technologies
105.00
-10.55
-9.13%
Vivos Therapeutics Earnings Call Summary
Earnings Call Date: Nov 14, 2024 | % Change Since: -0.32% | Next Earnings Date: Mar 31, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted strong revenue growth, improved gross margins, and strategic expansions. However, increased net loss and cash burn, along with decreased VIP enrollment revenue, are notable challenges. The sentiment is balanced with positive growth countered by financial losses.Highlights
Revenue Growth
Third quarter 2024 total revenue was $3.9 million, a 17% increase from the same quarter in 2023, driven by increased product and service revenue.
Improved Gross Margin
Gross margin for the third quarter of 2024 improved to 60% from 53% in the third quarter of 2023.
Cost Reduction
Sales and marketing expenses decreased by 46% in the third quarter of 2024 compared to the same period last year, contributing to a reduction in operating loss.
Strategic Partnerships
Initiated a strategic marketing and distribution alliance with Rebis Health, expanding operations to new locations in Colorado.
FDA Clearances
Received FDA clearance for treating moderate to severe OSA in children ages 6 to 17, expanding treatment opportunities.
Lowlights
Net Loss Increase
Net loss for the third quarter of 2024 increased by 25% to $2.6 million compared to the same quarter in 2023, primarily due to changes in the fair value of a warrant liability.
Cash Burn Increase
Cash burn from operations for the first nine months of 2024 was $9.8 million, up from $9.2 million during the same period last year.
Decreased VIP Enrollment Revenue
Revenue from VIP enrollments decreased by 6% in the third quarter of 2024 due to a shift in sales and marketing strategy.
Company Guidance
During the Vivos Therapeutics Q3 2024 earnings call, the company reported a 17% increase in total revenue, reaching $3.9 million compared to $3.3 million in Q3 2023. Product revenue saw a significant 34% rise due to increased sales of Vivos appliances and a substantial 83% reduction in discounts. Gross profit improved by 34% to $2.3 million, with gross margins climbing to 60% from 53% in the prior year. Sales and marketing expenses dropped by 46% to $300,000, and general and administrative expenses fell 20% over the nine months ending September 30, 2024. Despite these positive metrics, net loss for the quarter increased by 25% to $2.6 million, primarily due to changes in the fair value of a warrant liability. Vivos also highlighted their strategic shift towards an alliance-based sales model with sleep centers, aiming to enhance patient access and reduce reliance on VIP enrollments.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.